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medicine outlets in Uganda
Catherine Birabwa1, Jude Murison2,3, Valerie Evans2*, Celestino Obua4, Amon Agaba1, Paul Waako5
and Allyson Pollock6Abstract
Objectives: Many low income countries struggle to provide safe and effective medicines due to poor public health
care infrastructure, budgetary constraints, and lack of human resource capacity. Private sector pharmacies and drug
shops are used by a majority of the population as an alternative to public pharmacies. This study looks at the
availability of six essential medicines in private drug outlets across Uganda.
Methods: A standardised medicines availability survey developed by the World Health Organization and Health
Action International was adapted for use in this project to collect availability data for six tracer medicines in 126
private medicine outlets across four districts in Uganda from September 2011 to October 2012.
Results: Artemisinin-based combination treatments and metformin were the most commonly found medicines in
the private medicine outlets surveyed. Ninty-nine percent of all outlets carried artemisinin-based combinations
while 93% of pharmacies and 53% of drug shops stocked metformin. Oxytocin was found in one third of outlets
surveyed. Fluoxetine was in 70% of pharmacies yet was not found in any drug shops. Rifampicin and lamivudine
were found infrequently in outlets across all districts; 10% and 2%, respectively. Not all brands found in surveyed
outlets were listed on the Ugandan National Drug Register. In particular, five unlisted brands of rifampicin were
found in private medicine outlets.
Conclusions: The regulatory process should be improved through the enforcement of outlet licensing and
medicine registration. Additional studies to elucidate the reasons behind the use of private medicine outlets over
the public sector would assist the government in implementing interventions to increase use of public sector
medicine outlets.
Keywords: Essential medicines, Uganda, Medicine outlet, Pharmacy, Drug shop, Private sectorIntroduction
Medicines availability is a challenge for low income coun-
tries due to lack of resources for medicines and health
supplies, poor infrastructure and lack of workforce cap-
acity. Following the establishment of the WHO Model Es-
sential Medicines List (EML) in 1977, many countries
have adopted this concept in order to prioritise their me-
dicine needs [1]. Under the Ugandan National Drug Policy
essential medicines are a means of ensuring that safe, effi-
cacious and good quality medicines are available and ac-
cessible at all times and that they are affordable and used* Correspondence: v.evans@ed.ac.uk
2School of Social and Political Science, University of Edinburgh, Edinburgh,
UK
Full list of author information is available at the end of the article
? 2014 Birabwa et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.appropriately [2]. The Ugandan Ministry of Health? s first
national EML list (EMLU) was released in 1991 and is
updated approximately every five years, most recently in
2012 [3]. Although essential medicines should be freely
available at public health facilities this is not necessarily
the case forcing the population to rely on pharmacies and
drug shops in the private sector, particularly for obtaining
life-saving medicines [4-7]. Few studies have looked at the
availability of essential medicines in private outlets. In this
study, we conducted a survey of the availability of six
tracer medicines listed on the EMLU at private drug retail
outlets in Uganda.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Country and district demographics; total and
surveyed private medicine outlets
Region Population
coverage?
Medicine outlet type (outlets surveyed)
Pharmacy* Drug Shop
Country 34.0 million 510 5263**
Kampala 1,659,600 103 (45) Unknown (2)
Mbarara 83,700 15 (9) Unknown (28)
Bundibugyo 21,600 2 (2) Unknown (29)
Apac 13,700 0 (4) Unknown (7)
? Mid-year projection 2011 [26]; *NDA Registered Pharmacies [13]; **[9];
surveyed outlets are in parentheses.
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The public healthcare system is organised in four tiers:
community health teams at the local level, health centres
at the parish level, sub-county and constituency up to
the district level, and regional and national referral hos-
pitals which can provide comprehensive, specialist care.
In the public sector, vertical disease programmes provide
medicine consumption data and forecasts for malaria,
tuberculosis and HIV/AIDS. However, the private sector
makes up nearly 50% of healthcare delivery in Uganda and
is subdivided into formal and informal sectors [6,8-10].
The formal sector is comprised of private pharmacies,
drug shops, private clinics and private hospitals [2]. The
informal sector consists of general merchandise shops and
traditional practitioners [11]. Private retailers, both formal
and informal, are the major sources of medicines for
patients and require licenses from the National Drug
Authority (NDA) head office or Regional Inspectors of
Drugs [12]).
Medicine registration and scheduling
Most drugs that are authorised for use in Uganda are
listed on the National Drug Register (NDR) [12,13]. Fur-
thermore, the National Drug Policy and Authority Act
1993 provides information about which drugs can be
sold by pharmacies and drug shops [14]. Medicines are
classified into four schedules: Class A drugs (or narcotics)
may be sold by retail only with a prescription and may be
supplied only by a registered pharmacist or licensed phar-
macy under specific guidelines issued by the NDA; Class
B drugs (or controlled drugs) are divided into two groups:
group I (prescription-only medicines) may be supplied
only with a prescription and group II (pharmacy-initiated
medicines) may be supplied without a prescription only by
a registered pharmacist or licensed pharmacy; Class C
drugs (or licensed/over-the-counter drugs) may be sold by
a person or company operating a licensed pharmacy or by
a licensed drug seller (according to the specifications of
the license); the fourth schedule identifies medicines and
articles exempt from regulation by the NDA. While phar-
macies can avail all classes of medicines, drug shops are
restricted to Class C drugs.
Pharmacy and drug shop licensing and the law
By law, the NDA must register all drugs shops and phar-
macies annually. However, the licensing of pharmacies
and drug shops is managed at the regional authority of-
fices. Pharmacies predominantly exist in urban areas,
while drug shops are distributed evenly in rural areas
[15]. Qualitative studies in Uganda have highlighted prob-
lems associated with drug outlets including; inadequate
information given to patients, irrational drug sales, or the
inappropriate use of medicines and illegal sale of prescrip-
tion drugs [15-19].Methods
The World Health Organization/Health Action Inter-
national standard survey methodology was used to de-
velop a data collection tool for private sector medicine
outlets for six tracer medicines [20]. The six tracer med-
icines in this study are: artemether-lumefantrine for mal-
aria, metformin for diabetes, oxytocin, a uterotonic used
during labour, fluoxetine for mental illness, rifampicin
for tuberculosis, and lamivudine for HIV/AIDS. These
medicines were chosen to reflect the current disease
burden in Uganda for both communicable and non-
communicable diseases, and for vertical and non-vertical
programmes. All six of these tracer medicines are sched-
uled as Class B drugs in Uganda.
Sampling of medicine outlets
Four districts were chosen on the basis of health service
delivery performance rankings of districts across Uganda:
Kampala (highest performing), Mbarara (mid-upper per-
forming), Apac (mid-low performing) and Bundibugyo
(least performing) were selected [21,22]. A list of regis-
tered pharmacies in Kampala was obtained from the NDA
and a list of drug outlets for Mbarara, Apac and Bundibu-
gyo were obtained from the District Offices. If the selected
pharmacy/drug shop was closed or relocated the data col-
lector went to the nearest private medicine outlet. The
number of outlets surveyed by district and outlet type is
shown in Table 1. Of the 126 outlets, 47 were in Kampala,
37 in Mbarara, 31 in Bundibugyo, and 11 in Apac. Overall,
60 registered pharmacies and 66 drug shops were sampled
for this study (Table 1).
Data collection and analysis
Data were collected from September 2011 to October
2012. One hundred and twenty-six medicine outlets were
surveyed and semi-structured questionnaires were admin-
istered to the pharmacist or drug shop owner. Survey re-
sults were double entered into EpiInfo (v3.5.3) and
cleaned by the data manager. Data analysis was carried
out with EpiInfo and Microsoft Excel. Descriptive analysis
was performed to compare availability of medicines in
Table 2 Availability of tracer medicines in private drug outlets surveyed in four districts in Uganda
TM All outlets Kampala Mbarara Bundibuygo Apac Outlet type
(n = 126) (n = 47) (n = 37) (n = 31) (n = 11) Pharmacies Drug shops
(n = 60) (n = 66)
ART 124 (98%) 46 (98%) 37 (100%) 30 (97%) 11 (100%) 59 (98%) 65 (99%)
MET 91 (72%) 46 (98%) 26 (70%) 16 (52%) 3 (27%) 56 (93%) 35 (53%)
OXY 46 (37%) 21 (45%) 13 (36%) 10 (32%) 2 (18%) 27 (45%) 19 (29%)
FLU 42 (33%) 34 (72%) 7 (19%) 1 (3%) 0 42 (70%) 0
RIF 12 (10%) 8 (17%) 2 (6%) 2 (7%) 0 11 (18%) 1 (2%)
LAM 2 (2%) 2 (4%) 0 0 0 2 (3%) 0
ART = artemisinin-based combinations; MET =metformin; OXY = oxytocin; FLU = fluoxetine; RIF = rifampicin; LAM = lamivudine.
Table 3 Availability of tracer medicine brands listed on
the National Drug Register (NDR) as of July 2013 (NDR
updated 07/16/2013 and accessed 8/15/2013)
ART MET OXY FLU RIF LAM
No. brands on the NDR 72 40 6 3 9 71
No. brands in outlets 13 12 4 4 6 2
% NDR brands in all outlets 18% 28% 33% 100% 11% 3%
Outlet type Pharmacies 12 12 3* 4* 6* 2
Drug shops 10 6* 2* 0 1 0
District Kampala 8 5 2 4* 4* 2
Mbarara 11 10* 2* 3 1 0
Apac 5 4 1 0 0 0
Bundibuygo 7 2 2* 1 1 0
Brands not on the NDR 0 1 2 1 5 0
*Location where brands not on NDR were found.
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using the number of tracer medicines found as a percent-
age of the total number of surveyed outlets (Table 2 and
Table 3). The NDR from 2011 was reviewed to obtain in-
formation on total number and individual brands of each
tracer medicine registered and therefore legally allowed to
be on market in the country.
Ethical considerations
The study protocol was approved by the Institutional
Research Committee of Mbarara University of Science
and Technology and the Uganda National Council for
Science and Technology.
Results
Availability of tracer medicines in pharmacies and drug
shops
The availability of the six tracer medicines varied by
outlet type and location (Table 2). Artemisinin-based
combinations and metformin were the most prevalent
products. Artemisinin-based combination treatments were
found in nearly all pharmacies and drug shops (98%).
Metformin was found mainly in urban areas, as was flu-
oxetine. About 29% of drug shops stocked oxytocin. Ri-
fampicin was also minimally available across medicine
outlets and regions; 9.6% of total outlets surveyed. Only
2 pharmacies in Kampala stocked lamivudine, a drug
used for the treatment of HIV.
Registered and unregistered brands
The brands of the six tracer medicines in the surveyed
outlets were compared with those registered on the
NDR (Table 3). Of the 72 registered brands on the NDR
of artemisinin-based combination treatments only 13
were available in outlets (approximately 18%). Of the 40
brands of metformin, 12 were available. All three brands
of fluoxetine were available. For oxytocin and rifampicin,
4 out of 6 and 6 out of 9 registered brands were avail-
able, respectively. Seventy-one brands of lamivudine are
registered with the NDA in Uganda however only 2 were
found in pharmacies. Nine unregistered brands werefound in 28 medicine outlets (Table 4). Unlisted generic
metformin was found in Mbarara drug shops. Pitocin,
the oxytocin innovator, was found in 15 pharmacies and
drug shops in Mbarara and Bundibugyo. Fluoxetine was
only found in a few pharmacies; however, Prozac, the
unlisted innovator brand, was found in a pharmacy in
Kampala. Five unregistered brands of single drug for-
mulation of rifampicin that originated in Kenya and one
from India were found in pharmacies in Kampala. Overall,
there were 9 unregistered medicines found in the outlets
surveyed; 3 of these medicines were originator brands of
oxytocin and fluoxetine. The locations where these un-
registered medicines were found are listed in Table 3.
Discussion
Private drug outlets play a major role in selling essential
medicines especially when the public health system is
unreliable due to issues with procurement or stockouts
[23]. The six tracer medicines investigated for this study
are first-line treatments for common ailments and should
be available free at the point of use in the public sector.
The presence of these medicines in the private outlets high-
lights the existing gaps in the public sector. The presence of
Table 4 List of individual tracer medicine brands available in private drug outlets and frequency of brands available in outlets surveyed
TM Formulation & strength Brands License holder Country of
manufacture
Frequency of brand
in total outlets
surveyed
Frequency of brand
in total pharmacies
surveyed
Frequency of brand
in total drug shops
surveyed
(n = 126) (n = 60) (n = 66)
ART Artemether/Lumefantrine 20/120 mg (tablet) Lonart Bliss GVS Pharma India 68 38 30
Coartem (Innovator) Novartis USA/Switzerland 56 35 21
Lumartem Cipla Ltd/Quality Chemicals India/Uganda 43 20 23
Artefan Ajanta Pharma India 36 15 21
Lumether Astra Life Care India 9 0 9
Lumiter Macleods Pharmaceuticals Ltd India 2 0 2
Artesunate/Mefloquine 600/750 mg (tablet) Artequin Mepha Ltd Switzerland 2 1 1
Artemesinin/Nepthoquin 250/100 mg
(tablet)
Arco Kunming Pharmaceutical Co China 11 9 2
Artesunate/Amodiaquine 50/200 mg (tablet) Artesunate/
Amodiaquine
Winthrop
Sanofi Aventis Morocco 2 1 1
Falcimon-kit Cipla Ltd India 2 2 0
Dihydroartemisinin/ Piperaquine 40/320 mg
(tablet)
Duo-cotexcin Beijing Holley Cotec Pharmaceutical
Co Ltd
China 17 13 4
P-alaxin Bliss GVS Pharma India 8 6 2
Artemether 100 mg/ml (injection) Artenam Arenco Pharmacuetica NV Belgium 1 0 1
MET Metformin 500 mg (tablet) Glyformin 500 Remedica Ltd Cyprus 72 49 23
Glycomet 500 USV Ltd India 28 22 6
Metformin-denk 500 Denk Pharma GMPH & CO KG Germany 17 16 1
Glucophage
(Innovator)
Merck (PTY) Ltd France & South
Africa
13 12 1
Formin 500* Stadmed Pvt Ltd India 4 1 3
Bigomet 500 Aristo Pharmaceuticals Pvt Ltd India 2 1 1
Metchek 500 Indoco Remedies Ltd India 2 1 1
Metformin 850 mg (tablet) Glycomet 850 USV Ltd India 1 0 1
Metformin 1000 mg (tablet) Glycomet 1000SR USV Ltd India 1 1 0
Metformin denk Denk Pharma GMPH & CO KG Germany 1 1 0
Ranophage OD Ranbaxy Laboratories Ltd India 1 1 0
Metformin/Glibenclamide500/5 mg (tablet) Duotrol USV Ltd India 4 4 0
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Table 4 List of individual tracer medicine brands available in private drug outlets and frequency of brands available in outlets surveyed (Continued)
OXY Oxytocin 5 IU 5 IU/ml (ampoule) Oxytocin Win-Medicare India 21 21 0
Pitocin (Innovator)* Pfizer Ltd India 1 0 1
Oxytocin 10 IU 10 IU/ml (ampoule) Pitocin* Pfizer Ltd India 14 2 12
Oxytocin IDA/Astra Pharma (U) Ltd/Tata (U)
Ltd/Gittoes Pharmaceuticals Ltd
China/India/
Pakistan
3 3 0
FLU Fluoxetine hydrochloride 20 mg (capsule) Nuzac 20 Cipla Ltd India 18 18 0
Fluoxetine Cadila Healthcare Ltd India 14 14 0
Fludac Cadila Pharmaceuticals Ltd India 9 9 0
Prozac (Innovator)* Eli Lilly & Co USA 1 1 0
RIF Rifampicin 300 mg (tablet) Unirif 300* Universal Pharmacy (K) Ltd Kenya 3 3 0
Tikocin 300* Flamingo Pharmaceuticals Kenya 2 2 0
Rifacos* Cosmos Ltd Kenya 1 1 0
Rifampicin* Sino-Kenya Pharmaceuticals
Ltd/Panacea Biotech/Cosmos
Ltd/El-Nasr Pharm
Kenya 1 1 0
Rifampicin/Isoniazid 150/75 mg (tablet) Rihide 150 Cosmos Ltd Kenya 4 4 0
Rifampicin/Isoniazid/ Ethambutol/Pyrizinamide
150/75/275/400 mg (tablet)
ForeCox-Trac 150* Macleods Pharmaceuticals Ltd India 1 1 0
LAM Lamivudine 150 mg (tablet) Epivir (Innovator) Glaxo Wellcome (Kenya) Ltd South Africa 1 1 0
Lamivudine Aurobindo Pharma Ltd/Strides
Arcolab Ltd/Mylan Laboratories/
Hetero Drugs Ltd/Cipla Ltd
India 1 1 0
*Brands not on the NDR.
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gulatory enforcement and lack of access in the public
sector.
Pharmacy registration requires that a pharmacy be
manned by a licensed pharmacist, a requirement that may
not be met especially in rural regions due to the small
number of pharmacy professionals in the country, while a
drug shop can be registered by any health worker; i.e.
nurse, midwife clinical officer [6,24]. Lack of pharmacies,
especially in rural areas, together with inadequate enforce-
ment may be responsible for the presence of Class B drugs
in drug shops that fill the gap in availability.
Availability of tracer medicines in pharmacies and drug
shops
Uganda had over 12 million suspected cases of malaria
in 2011 that led to nearly 500,000 inpatient visits [25].
Almost all outlets surveyed carried artemisinin-based
malaria treatments, particularly artemether/lumefantrine,
which the Ugandan Clinical Guidelines recommends as
the first-line treatment for uncomplicated malaria [26]. Al-
though there is a vertical disease programme for malaria
no malaria-specific clinics exists in hospitals, as patients
are able to seek malaria treatment at virtually any health-
care facility. The Malaria Control Programme guarantees
the availability of antimalarials as part of the national
programme for controlling malaria.
Metformin is the most common worldwide treatment of
Type 2 Diabetes. The requirement of daily treatment for
this chronic condition explains the presence of this medi-
cine in many drug outlets surveyed across all districts.
Oxytocin has many obstetric uses and is listed in the
Ugandan Clinical Guidelines for induction of labour in
certain circumstances or management of post-partum
haemorrhage. It requires cold storage and only available
as an injectable and therefore requires specific storage
conditions and trained personnel to deliver the medica-
tion. The presence of oxytocin at drug shops is of major
concern, as they have no facility for cold storage.
Fluoxetine has recently been added to Uganda? s EML
in 2012, but has not yet been added to the treatment
guidelines. This survey found fluoxetine only available in
urban pharmacy outlets suggesting treatments for de-
pression are only just beginning to enter the market
place in Uganda.
Treatments for TB, HIV, and malaria are managed by
the Ministry of Health through national drug programmes
with separate clinics in public hospitals handling HIV and
TB patients. In some cases joint HIV and TB clinics exist
to simplify treatment regimens for patients.
Rifampicin is a powerful antibiotic and should not be
purchased as a single formulation. Ugandan policy states
rifampicin should only be used to treat TB and leprosy
and ideally as part of a combination therapy. The use ofrifampicin is restricted to combination treatment regi-
mens to prevent antibacterial resistance from deve-
loping. Two-, 3- or 4-medicine fixed dose combinations
that include rifampicin are available for the treatment
of tuberculosis and are listed as such in the EMLU.
Very few outlets surveyed carried rifampicin products.
This could indicate strong support for programme
medicines being available freely in the public healthcare
system or widespread stockouts at the time the survey
was conducted. It could be found in drug shops in
order to treat other infections such as brucellosis.
Treatment of HIV infection and prevention of mother
to child transmission both utilise lamivudine as part of a
combination therapy and therefore it is listed on the
EMLU as both a single formulation and a component of
fixed-dose combinations. Because the majority of antire-
trovirals now are combined formulations, primarily as a
means of limiting pill burden, lamivudine monotherapy
stocks are limited. Therefore lamivudine was not found
in many outlets possibly due to its availability in the
public sector through vertical programmes, restrictions
on pharmacies preventing them from stocking antiretro-
virals, or medicine stockouts during the survey. Lami-
vudine monotherapy can also used to treat Hepatitis B
infection, which may also explain some of the availability.
Availability of different brands of tracer medicines in
pharmacies and drug shops
The NDA has registered many brands, most of which
were produced in India and the USA. The absence of
African-produced brands, with the exception of South
African metformin and lamivudine and Kenyan rifampi-
cin (Table 4), may be due to consumer preferences for
overseas products due to quality perceptions (fieldwork
notes; Sep 2011 ? Oct 2012). Only a small percentage of
brands of the tracer medicines listed on the drug registry
were actually found in our outlet survey (Table 3). The
highest number of registered brands was for artemisinin-
based combinations and lamivudine, both of which are
available through vertical programmes that are freely
available to the public.
Availability of Non registered brands in pharmacies and
drug shops
Registration of medicines with the NDA is a legal require-
ment however unregistered products were found in sur-
veyed drug shops and pharmacies including: 1 fluoxetine,
1 metformin, 2 oxytocin, and 5 rifampicin. In this study it
is mainly brands of rifampicin, a highly regulated drug,
that were unregistered. Unregistered brands of rifampicin
were found in 6 pharmacies surveyed in Kampala (13% of
total) and 1 pharmacy each in Mbarara and Bundibugyo.
Pitocin was found in 20% of drug shops surveyed in
Bundibugyo and 25% of drug shops surveyed in Mbarara.
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The presence of unauthorised drugs on the market has
been attributed to the illegal operation of drug outlets
[12]. Uganda? s porous borders allow illegal products to
reach the market.
Limitations
Medicine registration data were limited to the NDA? s on-
line database and the time when it was accessed in July
2013. An accurate number of drug shops in each district
were not readily available so the sampling framework
was based on an approximation, which may result in a
biased sample and therefore not be truly representative.
The availability of medicines refers only to the day of
data collection; no assumptions of availability over time
can be determined from this study.
Conclusions
Few studies have investigated the availability of essential
medicines in private medicine outlets. This study shows
that some essential medicines are quite common in pri-
vate outlets and sold in drug shops that do not have a li-
cense for sale. In addition, only a few of the brands on the
NDR were present in outlets surveyed. The presence of
unauthorised formulations indicates weak enforcement.
Most of the available products were imported from India;
and locally manufactured products were not common.
In order to increase access to safe and effective essen-
tial medicines throughout the private sector in Uganda,
three areas can be improved upon. Firstly, enhance and
strengthen the regulation and enforcement of valid li-
censing of pharmacies and drug shops specifically in re-
spect to the class of drugs being offered. Secondly,
review medicine registration procedures within the NDA
and ensure the NDR is kept up-to-date and review the
need for so many brands. Lastly, investigate the reasons
why patients are using the private sector to obtain cer-
tain essential medicines that should be available free in
public facilities and what should be done about this.
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